- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04929041
Testing av tillegg av strålebehandling til vanlig behandling (immunterapi med eller uten kjemoterapi) for stadium IV ikke-småcellet lungekreftpasienter som er PD-L1-negative
En randomisert fase II/III-studie av moderne immunterapibasert systemisk terapi med eller uten SBRT for PD-L1-negativ, avansert ikke-småcellet lungekreft
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
- Annen: Quality-of-Life Assessment
- Fremgangsmåte: Biospecimen Collection
- Biologisk: Ipilimumab
- Fremgangsmåte: Computed Tomography
- Fremgangsmåte: Magnetic Resonance Imaging
- Fremgangsmåte: Echocardiography Test
- Fremgangsmåte: Positron Emission Tomography
- Biologisk: Nivolumab
- Stråling: Radiation Therapy
- Fremgangsmåte: Biopsy Procedure
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To assess if radiation improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage non-small cell lung cancer (NSCLC) patients with PD-L1 tumor proportion score (TPS) < 1% who receive immunotherapy with or without chemotherapy.
SECONDARY OBJECTIVES:
I. To estimate and compare the rates of >= grade 3-4 and all grade adverse events by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 between the arms.
II. To summarize and compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) between the arms.
III. To determine and compare the objective response rate (ORR) per RECIST between the arms (including at both irradiated and un-irradiated sites).
QUALITY OF LIFE (QOL) OBJECTIVE:
I. To assess the health-related QOL in both treatment arms.
CORRELATIVE SCIENCE OBJECTIVE:
I. To evaluate changes in the peripheral immune microenvironment between the arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as echocardiography (ECHO) during screening.
Arm B: Patients receive nivolumab IV over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.
After completion of study treatment, patients are followed up every 3 months for 3 years and then every 6 months for years 4-5 following randomization until disease progression. Following disease progression patients are followed for survival every 6 months for up to 5 years following randomization.
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85054
- Mayo Clinic Hospital in Arizona
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Berkeley, California, Forente stater, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte, California, Forente stater, 91010
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Forente stater, 92618
- City of Hope at Irvine Lennar
-
Lancaster, California, Forente stater, 93534
- City of Hope Antelope Valley
-
Marysville, California, Forente stater, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Forente stater, 95355
- Memorial Medical Center
-
Napa, California, Forente stater, 94558
- Providence Queen of The Valley
-
Sacramento, California, Forente stater, 95817
- University of California Davis Comprehensive Cancer Center
-
South Pasadena, California, Forente stater, 91030
- City of Hope South Pasadena
-
Truckee, California, Forente stater, 96161
- Gene Upshaw Memorial Tahoe Forest Cancer Center
-
Upland, California, Forente stater, 91786
- City of Hope Upland
-
-
Colorado
-
Colorado Springs, Colorado, Forente stater, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Forente stater, 80920
- Memorial Hospital North
-
Fort Collins, Colorado, Forente stater, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Forente stater, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Forente stater, 80631
- UCHealth Greeley Hospital
-
Loveland, Colorado, Forente stater, 80538
- Medical Center of the Rockies
-
-
Delaware
-
Millville, Delaware, Forente stater, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Forente stater, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Forente stater, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Forente stater, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Aventura, Florida, Forente stater, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Clearwater, Florida, Forente stater, 33756
- Morton Plant Hospital
-
Coral Gables, Florida, Forente stater, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Forente stater, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Forente stater, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Forente stater, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Forente stater, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Tampa, Florida, Forente stater, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Winter Haven, Florida, Forente stater, 33881
- Winter Haven Hospital
-
-
Georgia
-
Newnan, Georgia, Forente stater, 30265
- CTCA at Southeastern Regional Medical Center
-
Savannah, Georgia, Forente stater, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise, Idaho, Forente stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Forente stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forente stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forente stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Forente stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University
-
Chicago, Illinois, Forente stater, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Forente stater, 60612
- University of Illinois
-
Danville, Illinois, Forente stater, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Forente stater, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Forente stater, 62526
- Decatur Memorial Hospital
-
Effingham, Illinois, Forente stater, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Forente stater, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Forente stater, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Forente stater, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Forente stater, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey, Illinois, Forente stater, 60426
- Ingalls Memorial Hospital
-
Lake Forest, Illinois, Forente stater, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Forente stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Forente stater, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Forente stater, 62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park, Illinois, Forente stater, 60462
- University of Chicago Medicine-Orland Park
-
Rockford, Illinois, Forente stater, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Forente stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forente stater, 62702
- Springfield Clinic
-
Springfield, Illinois, Forente stater, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Forente stater, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Forente stater, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Crown Point, Indiana, Forente stater, 46307
- UChicago Medicine Northwest Indiana
-
-
Iowa
-
Ames, Iowa, Forente stater, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Forente stater, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Forente stater, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Forente stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forente stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Forente stater, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Forente stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forente stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forente stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Forente stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Forente stater, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Forente stater, 50266
- Mercy Medical Center-West Lakes
-
West Des Moines, Iowa, Forente stater, 50266
- The Iowa Clinic PC
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Forente stater, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
-
Maine
-
Sanford, Maine, Forente stater, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Forente stater, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Forente stater, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Forente stater, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Forente stater, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Forente stater, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Forente stater, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Forente stater, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Forente stater, 48118
- Chelsea Hospital
-
Flint, Michigan, Forente stater, 48503
- Hurley Medical Center
-
Flint, Michigan, Forente stater, 48503
- Genesys Hurley Cancer Institute
-
Kalamazoo, Michigan, Forente stater, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Forente stater, 49007
- Bronson Methodist Hospital
-
Lansing, Michigan, Forente stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Forente stater, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Forente stater, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Forente stater, 48341
- Michigan Healthcare Professionals Pontiac
-
Saginaw, Michigan, Forente stater, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Forente stater, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Forente stater, 48764
- MyMichigan Medical Center Tawas
-
West Branch, Michigan, Forente stater, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Forente stater, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Duluth, Minnesota, Forente stater, 55805
- Miller-Dwan Hospital
-
Minneapolis, Minnesota, Forente stater, 55415
- Hennepin County Medical Center
-
Robbinsdale, Minnesota, Forente stater, 55422
- North Memorial Medical Health Center
-
Saint Cloud, Minnesota, Forente stater, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Paul, Minnesota, Forente stater, 55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Forente stater, 63703
- Saint Francis Medical Center
-
Farmington, Missouri, Forente stater, 63640
- Parkland Health Center - Farmington
-
Rolla, Missouri, Forente stater, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Forente stater, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Forente stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forente stater, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Forente stater, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Forente stater, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Forente stater, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Bozeman, Montana, Forente stater, 59715
- Bozeman Health Deaconess Hospital
-
-
New York
-
Buffalo, New York, Forente stater, 14263
- Roswell Park Cancer Institute
-
Lake Success, New York, Forente stater, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, Forente stater, 10019
- Mount Sinai West
-
New York, New York, Forente stater, 10029
- Mount Sinai Hospital
-
New York, New York, Forente stater, 10011
- Mount Sinai Chelsea
-
New York, New York, Forente stater, 10075
- Lenox Hill Hospital
-
New York, New York, Forente stater, 10065
- Manhattan Eye Ear and Throat Hospital
-
Oswego, New York, Forente stater, 13126
- Upstate Cancer Center at Oswego
-
Oswego, New York, Forente stater, 13126
- Upstate Cancer Center Radiation Oncology at Oswego
-
Syracuse, New York, Forente stater, 13210
- State University of New York Upstate Medical University
-
Syracuse, New York, Forente stater, 13215
- SUNY Upstate Medical Center-Community Campus
-
Syracuse, New York, Forente stater, 13210
- Upstate Cancer Center at Hill Radiation Oncology
-
Verona, New York, Forente stater, 13478
- Upstate Cancer Center at Verona
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Duke University Medical Center
-
Raleigh, North Carolina, Forente stater, 27609
- Duke Cancer Center Raleigh
-
Winston-Salem, North Carolina, Forente stater, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Akron, Ohio, Forente stater, 44304
- Summa Health System - Akron Campus
-
-
Oklahoma
-
Lawton, Oklahoma, Forente stater, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Forente stater, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Forente stater, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Gresham, Oregon, Forente stater, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, Forente stater, 97239
- Oregon Health and Science University
-
Portland, Oregon, Forente stater, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Tualatin, Oregon, Forente stater, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, Forente stater, 19317
- Christiana Care Health System-Concord Health Center
-
Danville, Pennsylvania, Forente stater, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Forente stater, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Lewisburg, Pennsylvania, Forente stater, 17837
- Geisinger Medical Oncology-Lewisburg
-
Reading, Pennsylvania, Forente stater, 19605
- Penn State Health Saint Joseph Medical Center
-
Wilkes-Barre, Pennsylvania, Forente stater, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Medical University of South Carolina
-
-
Texas
-
Amarillo, Texas, Forente stater, 79106
- The Don and Sybil Harrington Cancer Center
-
-
Virginia
-
Richmond, Virginia, Forente stater, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Forente stater, 23298
- VCU Massey Comprehensive Cancer Center
-
Tappahannock, Virginia, Forente stater, 22560
- VCU Health Tappahannock Hospital
-
-
Washington
-
Vancouver, Washington, Forente stater, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Forente stater, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
Walla Walla, Washington, Forente stater, 99362
- Providence Saint Mary Regional Cancer Center
-
-
West Virginia
-
Charleston, West Virginia, Forente stater, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Ashland, Wisconsin, Forente stater, 54806
- Northwest Wisconsin Cancer Center
-
Eau Claire, Wisconsin, Forente stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
La Crosse, Wisconsin, Forente stater, 54601
- Gundersen Lutheran Medical Center
-
La Crosse, Wisconsin, Forente stater, 54601
- Mayo Clinic Health System-Franciscan Healthcare
-
Marshfield, Wisconsin, Forente stater, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Forente stater, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Forente stater, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Forente stater, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Forente stater, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Rice Lake, Wisconsin, Forente stater, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Forente stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Forente stater, 53188
- UW Cancer Center at ProHealth Care
-
Weston, Wisconsin, Forente stater, 54476
- Marshfield Medical Center - Weston
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologic or cytologic diagnosis of stage IV NSCLC using version American Joint Committee on Cancer (AJCC) 8th edition (includes M1a, M1b, and M1c stage disease). Patients with stage IIIB and IIIC disease are eligible if they are not a candidate for combined chemotherapy and radiation
- PD-L1 expression tumor proportion score (TPS) < 1% in tumor cells. If PD-L1 expression TPS is unevaluable or the testing could not be completed patients are not eligible. The assay must have been performed locally by a Clinical Laboratory Improvement Act (CLIA) (or equivalent) certified laboratory. The type of assay will be recorded
- For non-squamous patients only (adenocarcinoma or adenosquamous): EGFR, ALK and ROS1 testing must be done locally. No patients with known actionable EGFR mutations (except exon 20 insertion), ALK or ROS1 mutations that can be treated with oral tyrosine inhibitors
- Measurable disease based on RECIST 1.1, including at least two cancerous deposits. At least one deposit must be RECIST measurable (and not to be irradiated) while at least one OTHER deposit (measurable or non-measurable) must meet criteria for three 8 gray (Gy) doses of radiation
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- No more than three weeks of treatment with systemic chemotherapy or immunotherapy for advanced NSCLC
- No more than three weeks of treatment with checkpoint inhibitors for metastatic lung cancer
- No treatment with chemotherapy or immunotherapy for non-metastatic disease (e.g., adjuvant therapy) within 6 months prior to registration
- No systemic immunostimulatory or immunosuppressive drugs, including > 10 mg prednisone equivalent per day, within 2 weeks or 5 half-live of the drug, whichever is shorter. Steroid premedication per local standard is allowed
- >= 1 week prior to registration since palliative (including central nervous system [CNS]) radiotherapy to any tumor site
- No prior allogeneic tissue/solid organ transplant
- No uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study requirements
- No current pneumonitis or history of non-infectious pneumonitis that required steroids
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration
- No active auto-immune disease that requires systemic therapy within 2 years prior to registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- No known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection
- No patients with symptomatic central nervous system metastases and/or carcinomatous meningitis. Patients with small asymptomatic brain metastases are eligible as are patients with treated brain metastases that require no steroids
- Not pregnant and not nursing, because this study involves radiation as well as potentially chemotherapy which have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 7 days prior to registration is required
- No patients with a "currently active" second malignancy that is progressing or has required active treatment within the last 2 years. Participants with non-melanoma skin cancers or carcinoma in-situ (e.g., breast carcinoma, urothelial carcinoma or cervical cancer in situ) or localized prostate cancer (T1-3, N0, M0) that have undergone potentially curative therapy are eligible
- No hypersensitivity (>= grade 3) to immunotherapy and/or any of its excipients
- No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g.,FluMist [registered trademark]) are live attenuated vaccines and are not allowed. COVID-19 vaccine is allowed
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Calculated (Calc.) creatinine clearance >= 45 mL/min
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm A (immunotherapy, +/- chemotherapy)
Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Andre navn:
Undergo blood sample collection
Andre navn:
Given IV
Andre navn:
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Undergo ECHO
Andre navn:
Undergo PET
Andre navn:
Given IV
Andre navn:
Undergo tissue biopsy
Andre navn:
|
|
Eksperimentell: Arm B (immunotherapy, +/- chemotherapy, radiation therapy)
Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Andre navn:
Undergo blood sample collection
Andre navn:
Given IV
Andre navn:
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Undergo ECHO
Andre navn:
Undergo PET
Andre navn:
Given IV
Andre navn:
Undergo radiation therapy
Andre navn:
Undergo tissue biopsy
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free survival (PFS) (Phase II)
Tidsramme: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Will be performed on an intent-to-treat (ITT) basis. |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Overall survival (OS) (Phase III)
Tidsramme: From randomization and death of all causes, assessed up to 5 years
|
Will be performed on an ITT basis. The comparison of the distributions of OS between treatment arms will be done with a one-sided stratified log-rank test). The rates at various time points (e.g., every 6 months after randomization) and medians of OS for each arm will be estimated using the Kaplan-Meier estimator. The associated 95% confidence interval (CI) will be calculated using Greenwood's formula and based on a log-log transformation applied on the survival function. Hazard ratios will be estimated using a stratified Cox regression model. The final phase III analysis of OS will be considered as "positive" if the stratified log-rank test statistics Z-value greater than the critical value adjusted for type 1 error using group sequential methods. Multivariable Cox models will be used to evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, systemic therapy, histology and performance status. |
From randomization and death of all causes, assessed up to 5 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Livskvalitet
Tidsramme: Inntil 5 år
|
Inntil 5 år
|
|
|
PFS
Tidsramme: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Assessed per Response Evaluation Criteria in Solid Tumors (RECIST). |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Objective response rate (ORR)
Tidsramme: Up to 5 years
|
Assessed per RECIST for both irradiated and un-irradiated areas. The ORRs between treatments will be compared with Fisher's exact test. The difference of ORR between treatments will be estimated by the Miettinen-Nurminen method and its 95% CI will be given. Multivariable logistic regression will be used to evaluate the treatment effect on ORR while adjusting for significant baseline covariates. |
Up to 5 years
|
|
Incidence of treatment-related adverse events
Tidsramme: Up to 5 years
|
Treatment-related toxicity will be summarized by grade, type, and system organ class. Comparisons of the percentages of patients experiencing an adverse event between Arm A and Arm B will be performed using Fisher's exact test. |
Up to 5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Christine M Bestvina, Alliance for Clinical Trials in Oncology
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i luftveiene
- Neoplasmer etter histologisk type
- Lungesykdommer
- Neoplasmer, kjertel og epitel
- Adenokarsinom
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Karsinom
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Adenokarsinom i lungene
- Lungeneoplasmer
- Karsinom, ikke-småcellet lunge
- Aminosyrer, peptider og proteiner
- Proteiner
- Undersøkelsesteknikker
- Terapeutikk
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Kirurgiske prosedyrer, operativ
- Cytologiske teknikker
- Cytodiagnose
- Biologiske faktorer
- Fysiske fenomener
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Diagnostiske teknikker, kirurgisk
- Kjemisteknikker, analytisk
- Spektrumanalyse
- Reseptorer, celleoverflate
- Membranproteiner
- Antigener
- Antigener, overflate
- Biomarkører
- Reseptorer, immunologisk
- Antigener, differensiering, T-lymfocytt
- Antigener, differensiering
- Immunsjekkpunktproteiner
- Kostimulerende og hemmende T-celle reseptorer
- Nivolumab
- Ipilimumab
- Strålebehandling
- Stråling
- Biopsi
- Prøvehåndtering
- Magnetisk resonansspektroskopi
- CTLA-4 antigen
Andre studie-ID-numre
- NCI-2021-06042
- U10CA180821 (U.S. NIH-stipend/kontrakt)
- NCI-2021-06042 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- A082002 (Annen identifikator: CTEP)
- A082002 (Annen identifikator: Alliance for Clinical Trials in Oncology)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .